![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Update on Metformin NDMA Investigation Rules Out Recalls
FDA Update on Metformin NDMA Investigation Rules Out Recalls
![FDA_Logo_Blue_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Blue_2016.gif?t=1578316591&width=430)
February 7, 2020
The FDA said it found no metformin products that exceeded daily intake limits of N-Nitrosodimethylamine (NDMA) so it did not recommend recalling the type 2 oral diabetes drug in the U.S.
The agency’s investigation tested 16 lots of metformin products from seven different drugmakers: Actavis, Aurobindo, Heritage, Ingenus, Major, Sun Pharma and Westminster Pharmaceuticals.
All samples came back clean except for six Actavis lots that tested positive but for very low amounts.
Upcoming Events
-
21Oct